T. Rowe Price Associates
STAB

T. Rowe Price Associates’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

T. Rowe Price Associates’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-61,200
Closed -$5K – 3007
2022
Q4 		$5K Hold
61,200
– – ﹤0.01% 2917
2022
Q3 		$8K Hold
61,200
– – ﹤0.01% 2937
2022
Q2 		$17K Buy
61,200
+49,500
+423% +$12.8K ﹤0.01% 2937
2022
Q1 		$4K Buy
+11,700
New +$12.5K ﹤0.01% 2972
2021
Q1 		– Sell
-17,000
Closed -$59K – 2883
2020
Q4 		$59K Buy
+17,000
New +$48.4K ﹤0.01% 2645

Other funds holding STAB

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TAM
Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

T. Rowe Price Associates's STAB Position: Q1 2023 in Review

T. Rowe Price Associates sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 61,200 shares — an estimated $5K sold.

T. Rowe Price Associates first reported a position in STAB in Q4 2020 and held it in 5 quarters. The position peaked at $59K in Q4 2020. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

  • T. Rowe Price Associates reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 61,200 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $5K.
  • T. Rowe Price Associates first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • T. Rowe Price Associates's Statera Biopharma, Inc. Common Stock position peaked at $59K in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.